A Phase 3 interventional study of Niraparib and Abiraterone Acetate in Castration-Resistant Prostatic Cancer, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 318 sites in 29 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson — 3 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · Johnson & Johnson.
Among the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 3 in phase 3, and was the 7th registered.
85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.
Browse Prostatic Neoplasms, Castration-Resistant studies →3 of the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Australia, Belgium and 14 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Australia, Belgium and 14 more countries
Ages 18+ · Men only
Janssen Research & Development, LLC · Sites in Australia, Belgium, Denmark and 12 more countries
Ages 18+
By country, each count listing its studies:
Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 765 is above the median of 82 across 62 interventional studies indexed under Prostatic Neoplasms, Castration-Resistant.
Median enrollment 77 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225946Phase 3Janssen Research & Development, LLCA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | 2027-11-19 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
HRR gene alteration (as identified by the sponsor's required assays) as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg. In the open label extension (OLE) phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
Drug: Niraparib · Drug: Abiraterone Acetate · Drug: Prednisone · Drug: Placebo
Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
Drug: Niraparib · Drug: Abiraterone Acetate · Drug: Prednisone · Drug: Placebo
Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg.
Drug: Prednisone · Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)
Participants will receive niraparib 200 mg capsules or tablets once daily.
Also known as: JNJ-64091742
Participants will receive AA 1000 mg tablets once daily.
Participants will receive prednisone 10 mg tablets daily.
Participants will receive matching placebo once daily.
Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per response evaluation criteria in solid tumors (RECIST) 1.1; (2) Progression of bone lesions observed by bone scan based on prostate cancer working group 3 (PCWG3) criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan greater than or equal to (\>=) 6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan \>=2 new lesions indicate progression; scan does not show \>=2 new lesions means no progression. If Week 8 scan less than (\<) 2 new bone lesions compared to baseline, the initial scan \>=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan \>=6 weeks later.
Time frame: Up to 32 months
Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by CT or MRI as per RECIST 1.1; (2) Progression of bone lesions observed by bone scan based on PCWG3 criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan \>=6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan \>=2 new lesions indicate progression; scan does not show \>=2 new lesions means no progression. If Week 8 scan \<2 new bone lesions compared to baseline, the initial scan \>=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan \>=6 weeks later.
Time frame: Up to 32 months
Cohort 1: Overall Survival (OS)
Time frame: Up to 97 months
Cohort 1: Time to Symptomatic Progression
Time frame: Up to 97 months
Cohort 1: Time to Initiation of Cytotoxic Chemotherapy
Time frame: Up to 97 months
Observed Plasma Concentrations of Niraparib
Time frame: Up to 97 months
Observed Plasma Concentrations of Abiraterone
Time frame: Up to 97 months
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to 96 months
Number of Participants With Treatment-Emergent Adverse Events by Severity
Time frame: Up to 96 months
Number of Participants With Abnormalities in Laboratory Values
Time frame: Up to 96 months
| Milestone | Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg |
|---|---|---|---|---|---|
| Started | 212 | 211 | 123 | 124 | 95 |
| Breast cancer gene (brca) subgroup | 113 | 112 | 0 | 0 | 52 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 212 | 211 | 123 | 124 | 95 |
| Withdrew: Ongoing | 155 | 148 | 66 | 79 | 84 |
| Withdrew: Death | 54 | 59 | 51 | 42 | 9 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 5 | 3 | 2 |
As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per response evaluation criteria in solid tumors (RECIST) 1.1; (2) Progression of bone lesions observed by bone scan based on prostate cancer working group 3 (PCWG3) criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan greater than or equal to (\>=) 6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan \>=2 new lesions indicate progression; scan does not show \>=2 new lesions means no progression. If Week 8 scan less than (\<) 2 new bone lesions compared to baseline, the initial scan \>=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan \>=6 weeks later.
| Months | Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg |
|---|---|---|
| Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR) | 16.46 (13.83 to 19.38) | 13.70 (10.91 to 16.39) |
As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by CT or MRI as per RECIST 1.1; (2) Progression of bone lesions observed by bone scan based on PCWG3 criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan \>=6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan \>=2 new lesions indicate progression; scan does not show \>=2 new lesions means no progression. If Week 8 scan \<2 new bone lesions compared to baseline, the initial scan \>=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan \>=6 weeks later.
| Months | Cohort 1 BRCA Subgroup: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 1 BRCA Subgroup: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg |
|---|---|---|
| Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR) | 16.56 (13.86 to NA) | 10.87 (8.31 to 13.80) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Up to 32 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | 55/212 (25.9%) | 76/212 (35.8%) | 198/212 (93.4%) |
| Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | 59/211 (28%) | 52/211 (24.6%) | 178/211 (84.4%) |
| Cohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | 53/123 (43.1%) | 66/123 (53.7%) | 117/123 (95.1%) |
| Cohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | 44/123 (35.8%) | 45/123 (36.6%) | 108/123 (87.8%) |
| Cohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg | 9/95 (9.5%) | 21/95 (22.1%) | 83/95 (87.4%) |
| Event | Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 12/212 | 2/211 | 20/123 | 2/123 | 2/95 |
| PneumoniaInfections and infestations | 7/212 | 4/211 | 4/123 | 2/123 | 2/95 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 4/212 | 1/211 | 3/123 | 2/123 | 3/95 |
| Covid-19Infections and infestations | 6/212 | 1/211 | 3/123 | 0/123 | 0/95 |
| Cardiac FailureCardiac disorders | 1/212 | 1/211 | 3/123 | 0/123 | 0/95 |
| VomitingGastrointestinal disorders | 0/212 | 0/211 | 3/123 | 0/123 | 0/95 |
| SepsisInfections and infestations | 0/212 | 0/211 | 0/123 | 3/123 | 0/95 |
| Acute Kidney InjuryRenal and urinary disorders | 1/212 | 2/211 | 3/123 | 1/123 | 1/95 |
| Urinary RetentionRenal and urinary disorders | 4/212 | 2/211 | 0/123 | 3/123 | 0/95 |
| Urinary Tract InfectionInfections and infestations | 2/212 | 2/211 | 2/123 | 1/123 | 2/95 |
| Event | Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 95/212 | 43/211 | 59/123 | 19/123 | 37/95 |
| HypertensionVascular disorders | 66/212 | 44/211 | 41/123 | 27/123 | 15/95 |
| ConstipationGastrointestinal disorders | 65/212 | 29/211 | 38/123 | 25/123 | 23/95 |
| FatigueGeneral disorders | 56/212 | 35/211 | 29/123 | 21/123 | 16/95 |
| NauseaGastrointestinal disorders | 50/212 | 29/211 | 29/123 | 20/123 | 25/95 |
| Decreased AppetiteMetabolism and nutrition disorders | 30/212 | 13/211 | 29/123 | 11/123 | 13/95 |
| ThrombocytopeniaBlood and lymphatic system disorders | 45/212 | 18/211 | 24/123 | 3/123 | 11/95 |
| Back PainMusculoskeletal and connective tissue disorders | 31/212 | 44/211 | 19/123 | 25/123 | 7/95 |
| AstheniaGeneral disorders | 33/212 | 19/211 | 22/123 | 14/123 | 12/95 |
| NeutropeniaBlood and lymphatic system disorders | 28/212 | 12/211 | 21/123 | 6/123 | 7/95 |
| Age, Continuous(years) | Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 69.2 ± 8.79 | 68.6 ± 8.17 | 71.2 ± 7.11 | 71.1 ± 7.52 | 69.2 ± 8.99 | 69.7 ± 8.25 |
| Sex: Female, Male(Participants) | Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 212 | 211 | 123 | 124 | 95 | 765 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 26 | 25 | 8 | 12 | 12 | 83 |
| Not Hispanic or Latino | 166 | 169 | 110 | 105 | 77 | 627 |
| Unknown or Not Reported | 20 | 17 | 5 | 7 | 6 | 55 |
| Race (NIH/OMB)(Participants) | Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 0 | 1 | 3 |
| Asian | 29 | 41 | 45 | 37 | 14 | 166 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 5 | 0 | 0 | 0 | 3 | 8 |
| White | 160 | 153 | 72 | 83 | 70 | 538 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 17 | 16 | 5 | 4 | 7 | 49 |
| Region of Enrollment(Participants) | Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 2: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | Cohort 3: Niraparib 200 mg and Abiraterone Acetate 1000 mg FDC + Prednisone 10 mg | Total |
|---|---|---|---|---|---|---|
| ARGENTINA | 2 | 5 | 2 | 7 | 2 | 18 |
| AUSTRALIA | 15 | 12 | 12 | 9 | 3 | 51 |
| BELGIUM | 5 | 1 | 2 | 3 | 0 | 11 |
| BRAZIL | 20 | 14 | 0 | 0 | 10 | 44 |
| BULGARIA | 1 | 0 | 0 | 0 | 0 | 1 |
| CANADA | 4 | 7 | 1 | 4 | 3 | 19 |
| CHINA | 7 | 4 | 0 | 0 | 0 | 11 |
| CZECH REPUBLIC | 4 | 3 | 1 | 2 | 1 | 11 |
| FRANCE | 13 | 12 | 5 | 4 | 3 | 37 |
| GERMANY | 0 | 4 | 0 | 0 | 5 | 9 |
| HUNGARY | 7 | 4 | 3 | 2 | 1 | 17 |
| ISRAEL | 0 | 0 | 0 | 0 | 3 | 3 |
| ITALY | 9 | 10 | 3 | 3 | 11 | 36 |
| MALAYSIA | 5 | 10 | 17 | 7 | 1 | 40 |
| MEXICO | 3 | 2 | 0 | 0 | 0 | 5 |
| NETHERLANDS | 3 | 4 | 2 | 2 | 0 | 11 |
| POLAND | 12 | 12 | 11 | 15 | 4 | 54 |
| PORTUGAL | 1 | 1 | 0 | 0 | 3 | 5 |
| RUSSIAN FEDERATION | 19 | 21 | 6 | 1 | 3 | 50 |
| SOUTH KOREA | 8 | 22 | 21 | 17 | 10 | 78 |
| SPAIN | 12 | 9 | 9 | 12 | 3 | 45 |
| SWEDEN | 4 | 2 | 1 | 1 | 1 | 9 |
| TAIWAN | 8 | 4 | 7 | 12 | 3 | 34 |
| TURKEY | 18 | 16 | 6 | 6 | 5 | 51 |
| UKRAINE | 18 | 20 | 12 | 11 | 9 | 70 |
| UNITED KINGDOM | 2 | 1 | 0 | 3 | 3 | 9 |
| UNITED STATES | 12 | 11 | 2 | 3 | 8 | 36 |
Showing the first 100 of 318 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2019 to primary completion in Oct 2021, 32 months.
Results were first posted in Oct 2023, 1 year 11 months after primary completion. A results delay was requested in Oct 2022.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Niraparib · Abiraterone Acetate
Prostatic Neoplasms, Castration-Resistant →
Janssen Research & Development, LLC →